Concepedia

Joseph Glenn

JG

8

Publications

535

Citations

8

H-Index

2010

Active since

Affiliations

Incyte (United States)(Current)

Experimental Station

Pfizer (United States)

Joseph Glenn is an author at Incyte (United States) specializing in drug discovery, pharmacotherapy, and medicine.

Top concepts

Publications per year

2010–2019

8

Publications

8

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Eddy W. Yue, Richard Sparks, Padmaja Polam et al. · ACS Medicinal Chemistry Letters · 2017 · 290 citations · Full text

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist

Chu‐Biao Xue, Hao Feng, Ganfeng Cao et al. · ACS Medicinal Chemistry Letters · 2011 · 48 citations · Full text

, , +13

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)

Eddy W. Yue, Yunlong Li, Brent Douty et al. · ACS Medicinal Chemistry Letters · 2019 · 47 citations · Full text

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist

Chu‐Biao Xue, Anlai Wang, Qi Han et al. · ACS Medicinal Chemistry Letters · 2011 · 45 citations · Full text

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2

Chu‐Biao Xue, Anlai Wang, David Meloni et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 41 citations · Full text

, , +7

Rows per page

1–5 of 8